April 20, 2018 2:49 PM ET

Life Sciences Tools and Services

Company Overview of Metrion Biosciences Ltd

Company Overview

Metrion Biosciences Ltd offers drug discovery services. It also provides ion channel screening, cardiac safety screening, neuroscience, translational assays, and integrated drug discovery services. The company was founded in 2015 and is headquartered in Cambridge, United Kingdom.

Suite 1

Riverside 3

Granta Park

Great Abington

Cambridge,  CB21 6AD

United Kingdom

Founded in 2015

Phone:

44 1223 919 100

Key Executives for Metrion Biosciences Ltd

Metrion Biosciences Ltd does not have any Key Executives recorded.

Metrion Biosciences Ltd Key Developments

Metrion Biosciences Ltd Announces Director Changes

Metrion Biosciences has named Barry Kenny and Dr. Andrew Southan as its directors. Presently, Kenny is chief business officer of Heptares Therapeutics and was earlier vice president, drug discovery at Takeda. He has also held roles for Paradigm Therapeutics and Pfizer. Southan joined Metrion as head of commercial operations in October 2016, and was promoted to chief operating officer in April 2017. He has more than 25 years' experience in ion channel research and development and has held roles for Wyeth Research and Ionix Pharmaceuticals.

Metrion Biosciences Limited Enters into Agreement with LifeArc

Metrion Biosciences Limited has extended its existing partnership with LifeArc, a medical research charity, to support LifeArc neuroscience drug discovery programme. Under the terms of the agreement Metrion will provide validated ion channel and electrophysiology-based assays and safety profiling services, and LifeArc will conduct medicinal chemistry aimed at identifying novel modulators of an undisclosed CNS ion channel target. In addition, Metrion will contribute translational research expertise to evaluate the activity of LifeArc compounds in human neuronal networks. Metrion will provide translational assay support by applying its extensive background knowledge in ion channel research, microelectrode array technology, and access to its CiPA-compliant cardiac safety assays. This agreement enables Metrion Biosciences and LifeArc to support neuroscience small molecule drug discovery programme.

Similar Private Companies By Industry

Company Name Region
14M Genomics Ltd Europe
AB-Polyblok Ltd Europe
Ablatus Therapeutics Limited Europe
Accuro Biologics Ltd. Europe
ActinoPharma Limited Europe

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 16, 2018
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Metrion Biosciences Ltd, please visit www.metrionbiosciences.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.